ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Ongoing Trials Studying Immunotherapy as a First-Line Treatment in Head and Neck Cancer

Barbara Ann Burtness, MD
Published Online:4:50 PM, Mon October 3, 2016

Barbara Ann Burtness, MD, professor of medicine, Clinical Research Program Leader, Head and Neck Cancers Program and Co-Director, Developmental Therapeutics Research Program at Yale Cancer Center, discusses the ongoing trials looking at immunotherapy as a first-line treatment in head and neck cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.